105 related articles for article (PubMed ID: 16609031)
1. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.
Pruthi RS; Derksen JE; Moore D; Carson CC; Grigson G; Watkins C; Wallen E
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2172-7. PubMed ID: 16609031
[TBL] [Abstract][Full Text] [Related]
2. A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer.
Lin J; Zahurak M; Beer TM; Ryan CJ; Wilding G; Mathew P; Morris M; Callahan JA; Gordon G; Reich SD; Carducci MA; Antonarakis ES
Urol Oncol; 2013 Jul; 31(5):581-8. PubMed ID: 21816640
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study.
Keizman D; Zahurak M; Sinibaldi V; Carducci M; Denmeade S; Drake C; Pili R; Antonarakis ES; Hudock S; Eisenberger M
Clin Cancer Res; 2010 Nov; 16(21):5269-76. PubMed ID: 20978144
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy.
Pendleton JM; Tan WW; Anai S; Chang M; Hou W; Shiverick KT; Rosser CJ
BMC Cancer; 2008 May; 8():132. PubMed ID: 18471323
[TBL] [Abstract][Full Text] [Related]
5. Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer - a phase I study.
Ganswindt U; Budach W; Jendrossek V; Becker G; Bamberg M; Belka C
Radiat Oncol; 2006 Apr; 1():9. PubMed ID: 16722607
[TBL] [Abstract][Full Text] [Related]
6. A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer.
Dorff TB; Groshen S; Tsao-Wei DD; Xiong S; Gross ME; Vogelzang N; Quinn DI; Pinski JK
Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):359-65. PubMed ID: 25245366
[TBL] [Abstract][Full Text] [Related]
7. Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint.
Collins C; Carducci MA; Eisenberger MA; Isaacs JT; Partin AW; Pili R; Sinibaldi VJ; Walczak JS; Denmeade SR
Cancer Biol Ther; 2007 Sep; 6(9):1360-7. PubMed ID: 17786033
[TBL] [Abstract][Full Text] [Related]
8. A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study.
Ward JE; Karrison T; Chatta G; Hussain M; Shevrin D; Szmulewitz RZ; O'Donnell PH; Stadler WM; Posadas EM
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):87-92. PubMed ID: 22006050
[TBL] [Abstract][Full Text] [Related]
9. Liposomes for the treatment of prostate cancer therapy: A review.
Sahoo CK; Sahoo NK; Sahu M; Gupta J
Cancer Treat Res Commun; 2024; 39():100792. PubMed ID: 38367412
[TBL] [Abstract][Full Text] [Related]
10. Genomic tests for persistence PSA after radical prostatectomy: smoke and mirrors or new effective tools for the clinical decision-making?
Checcucci E; Oing C; Rescigno P
Minerva Urol Nephrol; 2023 Dec; 75(6):776-779. PubMed ID: 38126291
[No Abstract] [Full Text] [Related]
11. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy.
Smith MR; Manola J; Kaufman DS; Oh WK; Bubley GJ; Kantoff PW
J Clin Oncol; 2006 Jun; 24(18):2723-8. PubMed ID: 16782912
[TBL] [Abstract][Full Text] [Related]
12. The Potential Preventive and Therapeutic Roles of NSAIDs in Prostate Cancer.
Maghsoudi H; Sheikhnia F; Sitarek P; Hajmalek N; Hassani S; Rashidi V; Khodagholi S; Mir SM; Malekinejad F; Kheradmand F; Ghorbanpour M; Ghasemzadeh N; Kowalczyk T
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001694
[TBL] [Abstract][Full Text] [Related]
13. Should androgen deprivation therapy and other systemic treatments be used in men with prostate cancer and a rising PSA post-local treatments?
Patrikidou A; Zilli T; Baciarello G; Terisse S; Hamilou Z; Fizazi K
Ther Adv Med Oncol; 2021; 13():17588359211051870. PubMed ID: 34707693
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory cell-associated tumors. Not only macrophages (TAMs), fibroblasts (TAFs) and neutrophils (TANs) can infiltrate the tumor microenvironment. The unique role of tumor associated platelets (TAPs).
Dymicka-Piekarska V; Koper-Lenkiewicz OM; Zińczuk J; Kratz E; Kamińska J
Cancer Immunol Immunother; 2021 Jun; 70(6):1497-1510. PubMed ID: 33146401
[TBL] [Abstract][Full Text] [Related]
15. Anti-Inflammatory Drugs as Anticancer Agents.
Zappavigna S; Cossu AM; Grimaldi A; Bocchetti M; Ferraro GA; Nicoletti GF; Filosa R; Caraglia M
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32283655
[TBL] [Abstract][Full Text] [Related]
16. Cyclooxygenase-2 inhibitors delay relapse and reduce Prostate Specific Antigen (PSA) velocity in patients treated with radiotherapy for nonmetastatic prostate cancer: a pilot study.
King L; Christie D; Arora D; Anoopkumar-Dukie S
Prostate Int; 2020 Mar; 8(1):34-40. PubMed ID: 32257976
[TBL] [Abstract][Full Text] [Related]
17. Interdiction of Sphingolipid Metabolism Revisited: Focus on Prostate Cancer.
Voelkel-Johnson C; Norris JS; White-Gilbertson S
Adv Cancer Res; 2018; 140():265-293. PubMed ID: 30060812
[TBL] [Abstract][Full Text] [Related]
18. The impact of celecoxib on outcomes in advanced prostate cancer patients undergoing androgen deprivation therapy.
Etheridge T; Liou J; Downs TM; Abel EJ; Richards KA; Jarrard DF
Am J Clin Exp Urol; 2018; 6(3):123-132. PubMed ID: 30038944
[TBL] [Abstract][Full Text] [Related]
19. Cyclooxygenase 2: protein-protein interactions and posttranslational modifications.
Alexanian A; Sorokin A
Physiol Genomics; 2017 Nov; 49(11):667-681. PubMed ID: 28939645
[TBL] [Abstract][Full Text] [Related]
20. Do Aspirin and Other NSAIDs Confer a Survival Benefit in Men Diagnosed with Prostate Cancer? A Pooled Analysis of NIH-AARP and PLCO Cohorts.
Zhou CK; Daugherty SE; Liao LM; Freedman ND; Abnet CC; Pfeiffer R; Cook MB
Cancer Prev Res (Phila); 2017 Jul; 10(7):410-420. PubMed ID: 28507039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
